Saturday, October 31, 2026

XPO Logistics Stock Bullish Momentum With A 20% Rise In The Last 10 Sessions

XPO Logistics Stock Bullish Momentum With A 20% Rise In The Last 10 Sessions

(VIANEWS) - Shares of XPO Logistics (NYSE: XPO) rose by a staggering 20.62% in 10 sessions from $34.58 to $41.71 at 17:47 EST on Wednesday, after four sequential sessions in a row of losses. NYSE is falling 0.88% to $15,228.58, following the last session's downward trend.

XPO Logistics's last close was $43.07, 4.42% below its 52-week high of $45.06.

About XPO Logistics

XPO, Inc. provides freight transportation services in the United States, rest of North America, France, the United Kingdom, rest of Europe, and internationally. The company operates in two segments, North American LTL and European Transportation. The North American LTL segment provides customers with less-than-truckload (LTL) services, such as geographic density and day-definite domestic services. This segment also offers cross-border U.S., Mexico, Canada, and the Caribbean, as well as engages in the operation of trailer manufacturing. The European Transportation segment offers dedicated truckload, LTL, truck brokerage, managed transportation, last mile, freight forwarding and multimodal solutions, such as road-rail and road-short sea combinations. It provides its services to customers in various industries, such as industrial and manufacturing, retail and e-commerce, food and beverage, logistics and transportation, and consumer goods. The company was formerly known as XPO Logistics, Inc. and changed its name to XPO, Inc. in December 2022. XPO, Inc. was incorporated in 2000 and is based in Greenwich, Connecticut.

Earnings Per Share

As for profitability, XPO Logistics has a trailing twelve months EPS of $1.57.

PE Ratio

XPO Logistics has a trailing twelve months price to earnings ratio of 26.57. Meaning, the purchaser of the share is investing $26.57 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.12%.

Sales Growth

XPO Logistics's sales growth is negative 46.2% for the present quarter and negative 39.9% for the next.

Volatility

XPO Logistics's last week, last month's, and last quarter's current intraday variation average was 8.41%, 1.94%, and 2.98%.

XPO Logistics's highest amplitude of average volatility was 8.85% (last week), 2.91% (last month), and 2.98% (last quarter).

Yearly Top and Bottom Value

XPO Logistics's stock is valued at $41.71 at 17:47 EST, under its 52-week high of $45.06 and way higher than its 52-week low of $24.76.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, XPO Logistics's stock is considered to be oversold (<=20).

More news about XPO Logistics (XPO).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com